A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan (R2) Magnetic Resonance Imaging in B-thalassemia Subjects Administered SPD602 (SSP-004184AQ) or Exjade (Deferasirox) for Treatment of Chronic Transfusional Iron Overload

Trial Profile

A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan (R2) Magnetic Resonance Imaging in B-thalassemia Subjects Administered SPD602 (SSP-004184AQ) or Exjade (Deferasirox) for Treatment of Chronic Transfusional Iron Overload

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Deferitazole (Primary) ; Deferasirox
  • Indications Iron overload
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Aug 2014 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 27 May 2014 New source identified and integrated (European Clinical Trials Database EudraCT2013-000743-33).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top